Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 239Carcinoma, Non-Small-Cell Lung 237Prostatic Neoplasms 172Multiple Myeloma 154Neoplasms 136Colorectal Neoplasms 127Leukemia, Myeloid, Acute 123Lung Neoplasms 110Neoplasm Metastasis 101Squamous Cell Carcinoma of Head and Neck 94Carcinoma, Hepatocellular 91Melanoma 89Lymphoma 85Triple Negative Breast Neoplasms 77Pancreatic Neoplasms 77Ovarian Neoplasms 72Sarcoma 71Carcinoma, Renal Cell 66Brain Neoplasms 66Lymphoma, Large B-Cell, Diffuse 65Recurrence 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Head and Neck Neoplasms 57Lymphoma, Non-Hodgkin 56Leukemia, Lymphocytic, Chronic, B-Cell 55Stomach Neoplasms 54Hematologic Neoplasms 53Endometrial Neoplasms 53Urinary Bladder Neoplasms 51Small Cell Lung Carcinoma 50

Interventions

trastuzumab deruxtecan 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Unresectable Locally Recurrent Breast Cancer × 90 days × Clear all
NCT07497386 2026-05-11

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
150 enrolled
Breast

Unresectable Locally Recurrent Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡